回盛生物：预计2025年净利润同比增长1,265.93%-1,444.54%

Core Viewpoint - The company expects a significant increase in net profit for the fiscal year 2025, projecting between 235 million to 271 million yuan, representing a year-on-year growth of 1,265.93% to 1,444.54% [1] Group 1: Financial Performance - The company's net profit attributable to shareholders is expected to see substantial growth compared to the previous year, driven by increased operating revenue [1] - The anticipated growth in net profit is attributed to several factors, including revenue growth, technological innovation, improved utilization rates of formulations and active pharmaceutical ingredients, and rising prices of raw materials [1] Group 2: Market Expansion - During the reporting period, the company actively expanded both domestic and international markets, resulting in revenue growth in both areas [1]